Systemic Vasculitis: Clinical Trials

7 trials for Systemic Vasculitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 terminated. 7 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 27Terminated 7
Phase 31Terminated 1

Follow Systemic Vasculitis: new trials by email Literature Review of Systemic Vasculitis trials Research Report on Systemic Vasculitis

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
PR3-AAV Resilient Remission or PRRR
Obinutuzumab, Rituximab - Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Phase 2TerminatedMayo Clinic62023-06-302026-05-06
Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis
Rituximab, Infliximab, Tocilizumab - Giant Cell Arteritis, Takayasu Arteritis
Phase 2TerminatedCambridge University Hospitals NHS Foundation Trust222021-07-142025-06-17
Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA
IFX-1 low dose, IFX-1 high dose, Placebo - Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA)
Phase 2TerminatedInflaRx GmbH202018-10-152022-05-26
Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis
rituximab, Prednisone, Placebo - Cryoglobulinemia, Systemic Vasculitis
Phase 2TerminatedAssistance Publique - Hôpitaux de Paris142015-07-172019-03-18
Abatacept in ANCA Associated Vasculitis
Abatacept (Orencia) - ANCA-associated Vasculitis
Phase 2TerminatedImperial College London72007-11-012015-05-29
Rituxan in Churg Strauss Syndrome With Renal Involvement
Rituximab, Prednisone - Churg-Strauss Syndrome
Phase 2TerminatedFernando Fervenza42007-06-012011-12-08
Plasma Exchange for Renal Vasculitis
Plasma exchange, Intravenous methyl prednisolone, Methyl prednisolone - Wegener's Granulomatosis, Microscopic Polyangiitis
Phase 2 / Phase 3TerminatedCambridge University Hospitals NHS Foundation Trust1501995-03-012011-08-03

Narrower conditions

Granulomatosis with Polyangiitis (4)  ·  Microscopic Polyangiitis (4)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3)  ·  Churg-Strauss Syndrome (2)  ·  Vasculitis (2)  ·  Cogan Syndrome (1)  ·  Cryoglobulinemia (1)  ·  Cryoglobulinemia, Familial Mixed (1)  ·  Giant Cell Arteritis (1)  ·  Glomerulonephritis (1)  ·  IgA Vasculitis (1)  ·  Polyarteritis Nodosa (1)  ·  Polychondritis, Relapsing (1)  ·  Takayasu Arteritis (1)

Broader conditions

Cardiovascular Diseases (7)  ·  Immune System Diseases (7)  ·  Skin Diseases (7)  ·  Skin Diseases, Vascular (7)  ·  Skin and Connective Tissue Diseases (7)  ·  Vascular Diseases (7)  ·  Autoimmune Diseases (6)  ·  Brain Diseases (5)  ·  Central Nervous System Diseases (5)  ·  Cerebrovascular Disorders (5)  ·  Nervous System Diseases (5)  ·  Vasculitis (5)  ·  Cerebral Small Vessel Diseases (4)  ·  Hemic and Lymphatic Diseases (4)

Interventions

Rituximab (4)  ·  Prednisone (2)  ·  Abatacept (1)  ·  Infliximab (1)  ·  Plasma Exchange (1)  ·  obinutuzumab (1)  ·  tocilizumab (1)  ·  vilobelimab (1)

Sponsors

Cambridge University Hospitals NHS Foundation Trust (2)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Fernando Fervenza (1)  ·  Imperial College London (1)  ·  InflaRx GmbH (1)  ·  Mayo Clinic (1)

Countries

United Kingdom (3)  ·  United States (3)  ·  Canada (1)  ·  France (1)

Top investigators

Alan Salama (1)  ·  David Jayne (1)  ·  Fernando C. Fervenza, M.D., Ph.D. (1)  ·  Korinna Pilz, MD, MS (1)  ·  Niels Rasmussen, MD (1)  ·  Peter A. Merkel, MD, MPH (1)  ·  Ulrich Specks, MD (1)

Results publications

PMID 21325353, PMID 23615499, PMID 33164993

NIH funding

UL1RR024150 (1)